Experience with ponatinib in paediatric patients with leukaemia

Jenna Rossoff, Van Huynh, Rachel E. Rau, Margaret E. Macy, Maria L. Sulis, Kirk R. Schultz, Michael J. Burke, Uma Athale, Maureen M. O'Brien, John J. Gregory, Inge M. van der Sluis, Frank G. Keller, Christian M. Zwaan, Meinolf Suttorp, Nobuko Hijiya

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

12 Citaten (Scopus)

Samenvatting

Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. Among paediatric patients with chronic myeloid leukaemia (n = 9) or acute lymphoblastic leukaemia (n = 12) treated with varying doses of ponatinib in 13 centres, 71% showed a decrease in disease burden after a median of three months. Ponatinib was well tolerated, with grade 3 toxicities occurring in 29% of patients. Toxicities were similar to those reported in adults, with the exception of arterial thrombotic events, which were not observed. Ponatinib has a favourable safety profile in this paediatric cohort, but dose-finding studies are needed.

Originele taal-2Engels
Pagina's (van-tot)363-368
Aantal pagina's6
TijdschriftBritish Journal of Haematology
Volume189
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - 1 apr. 2020

Vingerafdruk

Duik in de onderzoeksthema's van 'Experience with ponatinib in paediatric patients with leukaemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit